Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear. The objective of this st…